Followers | 130 |
Posts | 14996 |
Boards Moderated | 1 |
Alias Born | 06/04/2018 |
![](https://investorshub.advfn.com/uicon/675392.png?cb=1562414338)
Wednesday, May 22, 2019 8:40:40 AM
SAN DIEGO and PENNINGTON, N.J. , May 22, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a late-stage cancer biotechnology company developing gene-based intratumoral immunotherapies, today announces interim data from KEYNOTE-890, an ongoing Phase 2 study of TA...
In case you are interested https://marketwirenews.com/news-releases/oncosec-provides-encouraging-interim-data-from-ongoing-keynote-890-study-of-tavo-in-combination-with-keytruda-xae-for-the-treatment-of-heavily-pretreated-chemotherapy-radiotherapy-refractory-metastatic-triple-negative-breast-cancer-8228844.html
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM